Innovid Reports Second Quarter 2022 Financial Results
Innovid Corp. reported a remarkable 45% year-over-year revenue growth in Q2 2022, achieving $33.1 million in revenue. CTV revenue contributed significantly, accounting for 50% of total video impressions served. The launch of InnovidXP, a cross-platform measurement solution, is expected to drive further growth. Despite a net profit of $4.3 million or $0.03 per share, adjusted EBITDA was negative at $(1.7) million. The company anticipates Q3 2022 revenue between $33 million to $35 million and full-year revenue in the range of $127 million to $132 million.
- 45% year-over-year revenue growth to $33.1 million.
- InnovidXP launch expected to enhance growth prospects.
- CTV accounted for 50% of total video impressions served.
- International revenue increased by 51% year-over-year.
- Adjusted EBITDA was negative at $(1.7) million.
- Third quarter adjusted EBITDA expected to remain negative or break even.
- Delivered
45% year-over-year revenue growth to$33.1 million on an as-reported basis - CTV accounted for
50% of the volume of all video impressions served - TV measurement accounted for
22% of all revenue - Launched InnovidXP – the first cross-platform TV measurement solution powered by ad serving data and creative personalization
NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Innovid Corp. (NYSE:CTV) (the "Company"), an independent advertising platform for delivery, personalization and measurement of converged TV across linear, connected TV (CTV) and digital, today announced financial results for the second quarter ended June 30, 2022.
"Innovid delivered a strong second quarter with
(All comparisons are to the second quarter of 2021)
• Revenue grew to
° TVSquared business grew
° CTV accounted for
• Net profit was
• Adjusted EBITDA* was negative
• CTV Volume Growth: CTV accounted for
• Cross-Platform Measurement Expansion: Launched InnovidXP, the first unified cross-platform solution directly integrated with ad serving data and creative personalization, to solve cross-platform TV measurement globally.
° New Business: Measurement accounted for
° Sell-Side Momentum: Expanded multi-year measurement partnership with Tubi, Fox's streaming service, demonstrating the power of InnovidXP for always-on incremental reach measurement across both Fox and Tubi.
• New Client Wins: Closed multiple new clients across ad serving and personalization solutions including a multinational e-commerce company, a multinational travel company, and one of the largest U.S. health insurance providers.
• International Market Adoption: Increased international revenue by
• Expanded Measurement Partnerships: Grew measurement footprint through strategic partnerships spanning programmatic, political, and international TV advertising.
° Programmatic CTV: Named a certified partner in Magnite's expanded measurement and attribution program, bringing currency optionality to programmatic CTV.
° Political TV Advertising: Partnered with leading ad intelligence data provider, AdImpact, to supply a unified view and real-time insights on reach, frequency, incremental reach, and outcomes, across linear and CTV.
° International Audience Measurement: Integrated within FreeWheel by Comcast's newly launched international AudienceXpress offering, allowing advertisers in Europe to buy premium TV advertising on an audience basis across all platforms.
Innovid is providing the following financial guidance for the third quarter of 2022:
• Revenue is expected to be in the range of
• Adjusted EBITDA* is expected to be in the range of negative
Innovid is providing the following updated financial guidance for the full year of 2022:
• Revenue is expected to be in the range of
• Total annual adjusted EBITDA* when accounting for the TVSquared acquisition, is expected to be negative
Innovid will host a conference call and live webcast to discuss its second quarter 2022 financial results and business highlights today at 8:00 a.m. Eastern Time. Speakers will include Zvika Netter, Co-founder and Chief Executive Officer, Tanya Andreev-Kaspin, Chief Financial Officer, and Tal Chalozin, Co-founder and Chief Technology Officer. To access the conference call, dial 877-407-3211 for the U.S. or Canada, or +1-201-389-0862 for international callers. The webcast will be available live on the Investors section of the Company's website at https://investors.innovid.com/. Additionally, an archived webcast of the conference call will be made available on the Innovid website following the call.
*This is a non-GAAP measure. Refer to "Non-GAAP Measures" section below for additional information.
Innovid prepares unaudited condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles ("GAAP"). Innovid also discloses and discusses non-GAAP financial measures such as Adjusted EBITDA and Adjusted EBITDA margin. Innovid believes that these measures are relevant and provide useful information to investors by providing a baseline for evaluation and comparing its operating performance against that of other companies in Innovid's industry. Adjusted EBITDA is defined as net income (loss) attributable to Innovid, excluding (1) depreciation and amortization, (2) stock-based compensation, (3) finance expense, net, (4) transaction related expenses, (5) acquisition related expenses, (6) taxes on income and (7) other one-time items. We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by total revenue.
The non-GAAP financial measures that Innovid uses may not be comparable to similarly titled measures reported by other companies. Also, in the future, Innovid may disclose different non-GAAP financial measures in order to help its investors meaningfully evaluate and compare its results of operations to its previously reported results of operations or to those of other companies in Innovid's industry. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.
Innovid uses Adjusted EBITDA and Adjusted EBITDA margin as measures of operational efficiency to understand and evaluate its core business operations. Innovid believes these non-GAAP financial measures are useful to investors for period to period comparisons of its core business and for understanding and evaluating trends in its operating results on a consistent basis by excluding items that are not viewed as indicative of its core operating performance.
Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as substitutes for an analysis of our results as reported under GAAP.
Innovid has provided a reconciliation of Adjusted EBITDA to net (loss) income and Adjusted EBITDA Margin to net (loss) income margin, the most directly comparable GAAP measures, for the historical period in the appendix hereto but is not able to provide a reconciliation of the projected non-GAAP measures for the second quarter of 2022 or the full-year 2022, without unreasonable effort, due to the unknown effect, timing and potential significance of: taxes on income in multiple jurisdictions, finance expenses including valuations, and purchase price allocation yet to be finalized. These items have in the past, and may in the future, significantly affect GAAP results in a particular period.
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1996. The Company's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," "aim," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations regarding its future financial results and expected growth. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results, including Innovid's ability to raise financing in the future, success in retaining or recruiting officers, key employees or directors, changes in applicable laws or regulations, Innovid's ability to maintain and expand relationships with advertisers, decreases and/or changes in CTV audience viewership behavior, Innovid's ability to make the right investment decisions and to innovate and develop new solutions, the accuracy of Innovid's estimates of
market opportunity, forecasts of market growth and projections of future financial performance, the extent of investment required in Innovid's sales and marketing efforts, Innovid's ability to effectively manage its growth, the impact of the Covid-19 pandemic, the risk of continued inflation and other macroeconomic events, acquisition related risks, and other important factors discussed under the caption "Risk Factors" in Innovid's Annual Report on Form 10-K filed with the SEC on March 18, 2022, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC's website at www.sec.gov and the Investors Relations section of Innovid's website at investors.innovid.com. Most of these factors are outside the Company's control and are difficult to predict. The Company cautions not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Innovid (NYSE:CTV) powers advertising delivery, personalization, measurement and outcomes across linear, CTV and digital for some of the world's largest brands. Through a global infrastructure that enables cross-platform ad serving, data-driven creative, and currency-grade measurement, Innovid offers its clients always-on intelligence to optimize advertising investment across channels, platforms, screens, and devices. Innovid is an independent platform that leads the market in converged TV innovation, through proprietary technology and exclusive partnerships designed to reimagine TV advertising. Headquartered in New York City, Innovid serves a global client base through offices across the Americas, Europe, and Asia Pacific. To learn more, visit innovid.com or follow us on LinkedIn or Twitter.
Investor Relations:
Brinlea Johnson
ir@innovid.com
Media:
Chris Harihar
chris@crenshawcomm.com
INNOVID, CORP. AND ITS SUBSIDIARIES | |||
June 30, 2022 | December 31, 2021 | ||
(Unaudited) | |||
ASSETS | |||
CURRENT ASSETS: | |||
Cash and cash equivalents | $ 44,024 | $ 156,696 | |
Trade receivables, net (allowance for doubtful accounts of | 43,553 | 35,422 | |
Prepaid expenses and other current assets | 5,247 | 3,131 | |
Total current assets | 92,824 | 195,249 | |
NON-CURRENT ASSETS: | |||
Long-term deposit | 312 | 310 | |
Long-term restricted deposits | 411 | 462 | |
Property and equipment, net | 8,862 | 4,840 | |
Goodwill | 114,608 | 4,555 | |
Intangible assets, net | 35,135 | — | |
Operating lease right of use asset | 3,069 | — | |
Other non-current assets | 625 | 116 | |
Total non-current assets | 163,022 | 10,283 | |
TOTAL ASSETS | $ 255,846 | $ 205,532 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
CURRENT LIABILITIES: | |||
Trade payables | 3,661 | 5,026 | |
Employees and payroll accruals | 9,499 | 7,742 | |
Accrued expenses and other current liabilities | 4,662 | 3,082 | |
Current portion of long-term debt | 15,000 | 6,000 | |
Lease liabilities - current portion | 1,685 | — | |
Total current liabilities | 34,507 | 21,850 | |
NON-CURRENT LIABILITIES: | |||
Lease liabilities - non-current portion | 2,464 | — | |
Other non-current liabilities | 3,831 | 3,455 | |
Warrants liability | 3,026 | 18,972 | |
Total non-current liabilities | 9,321 | 22,427 | |
TOTAL LIABILITIES | 43,828 | 44,277 | |
COMMITMENTS AND CONTINGENT LIABILITIES | |||
STOCKHOLDERS' EQUITY: | |||
Common stock of | 13 | 12 | |
Additional paid-in capital | 347,630 | 293,719 | |
Accumulated deficit | (135,625) | (132,476) | |
Total stockholders' equity | 212,018 | 161,255 | |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 255,846 | $ 205,532 | |
INNOVID, CORP. AND ITS SUBSIDIARIES | |||||||
Three months ended | Six months ended | ||||||
2022 | 2021 | 2022 | 2021 | ||||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||
Revenues | $ 33,088 | $ 22,842 | $ 58,950 | $ 40,855 | |||
Cost of revenues (1) | 7,351 | 3,968 | 13,277 | 7,811 | |||
Research and development (1) | 9,710 | 6,131 | 16,964 | 11,356 | |||
Sales and marketing (1) | 14,320 | 8,105 | 24,671 | 14,677 | |||
General and administrative (1) | 9,955 | 4,200 | 21,410 | 6,579 | |||
Depreciation and amortization | 926 | 149 | 1,599 | 331 | |||
Operating (loss) profit | (9,174) | 289 | (18,971) | 101 | |||
Finance expenses (income), net | (13,306) | 1,602 | (15,617) | 3,171 | |||
Profit (loss) before taxes | 4,132 | (1,313) | (3,354) | (3,070) | |||
Taxes on income (tax benefit) | (168) | 346 | (205) | 525 | |||
Net profit (loss) | 4,300 | (1,659) | (3,149) | (3,595) | |||
Accretion of preferred stock to redemption value | — | (21,076) | — | (44,804) | |||
Net loss attributable to common stockholders | $ 4,300 | $ (22,735) | $ (3,149) | $ (48,399) | |||
Net loss per stock attributable to common stockholders (2) | |||||||
Basic | $ 0.03 | $ (1.33) | $ (0.02) | $ (2.85) | |||
Diluted | $ 0.03 | $ (1.33) | $ (0.02) | $ (2.85) | |||
Weighted-average number of stock used in computing net loss per stock attributable to common stockholders (2) | |||||||
Basic | 132,152,652 | 17,116,586 | 128,220,893 | 16,956,139 | |||
Diluted | 139,988,123 | 17,116,586 | 128,220,893 | 16,956,139 | |||
(1) | Exclusive of depreciation and amortization presented separately. |
(2) | Prior period results have been adjusted to reflect the exchange of Innovid Inc's common stock for Innovid Corp's common stock at an exchange ratio of approximately 1.337 as a result of the Transaction. |
INNOVID, CORP. AND ITS SUBSIDIARIES | ||||||||||||||||||||
Temporary equity | Common stock | Treasury stock | Additional paid-in capital | Accumulated deficit | Total stockholders' equity (deficit) | |||||||||||||||
Number | Amount | Number | Amount | Number | Amount | |||||||||||||||
Balance as of December 31, 2020 | 73,690,340 | $ 86,997 | 16,275,609 | $ 2 | 1,914,328 | $ (1,629) | $ 10 | $ (48,113) | $ (49,730) | |||||||||||
Accretion of preferred stock to redemption value | — | 23,728 | — | — | — | — | (586) | (23,142) | (23,728) | |||||||||||
Stock-based compensation | — | — | — | — | — | — | 280 | — | 280 | |||||||||||
Stock options exercised | — | — | 761,697 | — | — | — | 306 | — | 306 | |||||||||||
Net loss | — | — | — | — | — | — | — | (1,936) | (1,936) | |||||||||||
Balance as of March 31, 2021 (unaudited) | 73,690,340 | 110,725 | 17,037,306 | 2 | 1,914,328 | (1,629) | 10 | (73,191) | (74,808) | |||||||||||
Accretion of preferred stock to redemption value | — | 21,076 | — | — | — | — | $ (1,500) | $ (19,576) | (21,076) | |||||||||||
Stock-based compensation | — | — | — | — | — | — | $ 1,440 | $ — | 1,440 | |||||||||||
Stock options exercised | — | — | 1,281,999 | — | — | — | $ 61 | $ — | 61 | |||||||||||
Net loss | — | — | — | — | — | $ — | $ — | $ (1,659) | (1,659) | |||||||||||
Balance as of June 30, 2021 (unaudited) | 73,690,340 | 131,801 | 18,319,305 | $ 2 | 1,914,328 | (1,629) | $ 11 | $ (94,426) | $ (96,042) | |||||||||||
Temporary equity | Common stock | Treasury stock | Additional paid-in capital | Accumulated deficit | Total stockholders' equity | |||||||||||||||
Number | Amount | Number | Amount | Number | Amount | |||||||||||||||
Balance as of December 31, 2021 | — | — | 119,017,380 | $ 12 | — | — | $ 293,719 | $ (132,476) | $ 161,255 | |||||||||||
Common stock and equity awards issued for acquisition of TVS | — | — | 11,549,465 | 1 | — | — | 47,151 | — | 47,152 | |||||||||||
Stock-based compensation | — | — | — | — | — | — | 1,496 | — | 1,496 | |||||||||||
Stock options exercised | — | — | 1,521,927 | — | — | — | 462 | — | 462 | |||||||||||
Net loss | — | — | — | — | — | — | — | (7,449) | (7,449) | |||||||||||
Balance as of March 31, 2022 (unaudited) | — | — | 132,088,772 | 13 | — | — | 342,828 | (139,925) | 202,916 | |||||||||||
Stock-based compensation | — | — | — | — | — | — | 4,628 | — | 4,628 | |||||||||||
Stock options exercised | — | — | 322,943 | — | — | — | 174 | — | 174 | |||||||||||
Net profit | — | — | — | — | — | — | — | 4,300 | 4,300 | |||||||||||
Balance as of June 30, 2022 (unaudited) | — | — | 132,411,715 | $ 13 | — | — | $ 347,630 | $ (135,625) | $ 212,018 | |||||||||||
INNOVID, CORP. AND ITS SUBSIDIARIES | |||
Six months ended June 30, | |||
2022 | 2021 | ||
Cash flows from operating activities: | (Unaudited) | (Unaudited) | |
Net loss | $ (3,149) | $ (3,595) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 1,599 | 331 | |
Stock-based compensation | 5,634 | 1,720 | |
Change in fair value of warrants | (15,946) | 2,728 | |
Changes in operating assets and liabilities | |||
(Increase)/ decrease in trade receivables, net | (4,624) | 2,605 | |
Increase in prepaid expenses and other operating assets | (747) | (623) | |
Increase/ (decrease) in trade payables | (321) | 238 | |
Decrease in operating lease right of use assets | 872 | — | |
Increase/ (decrease) in employees and payroll accruals | 1,044 | 184 | |
Decrease in operating lease liabilities | (1,208) | — | |
Increase in accrued expenses and other operating liabilities | 945 | 759 | |
Net cash (used in)/ provided by operating activities | (15,901) | 4,347 | |
Cash flows from investing activities: | |||
Acquisition of business, net of cash acquired | (99,568) | — | |
Internal use software capitalization | (3,516) | — | |
Purchase of property and equipment | (221) | (284) | |
Founders' note receivable | — | (459) | |
Decrease in deposits | 32 | (24) | |
Net cash used in investing activities | (103,273) | (767) | |
Cash flows from financing activities: | |||
Repayment of acquisition liability | — | (126) | |
Proceeds from loans | 9,000 | — | |
Repayment of loans | — | (3,033) | |
Payment of SPAC merger transaction costs | (3,185) | — | |
Proceeds from exercise of options | 636 | 367 | |
Net cash (used in)/ provided by financing activities | 6,451 | (2,792) | |
Increase/ (decrease) in cash, cash equivalents and restricted cash | (112,723) | 788 | |
Cash, cash equivalents and restricted cash at the beginning of the period | 157,158 | 16,092 | |
Cash, cash equivalents and restricted cash at the end of the period | $ 44,435 | $ 16,880 | |
Supplemental disclosure of cash flows activities: | |||
(1) Cash paid during the period for: | |||
Income taxes paid, net of tax refunds | $ 363 | $ 80 | |
Interest | $ 137 | $ 128 | |
(2) Non-cash transactions: | |||
Business combination consideration paid in stock | $ 47,152 | $ — | |
Accretion of preferred stock to redemption value | — | $ 44,804 | |
Deferred offering cost included in accrued liabilities | — | $ 1,640 | |
Reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position | |||
Cash and cash equivalents | 44,024 | 16,441 | |
Long-term restricted deposits | 411 | 439 | |
Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows | $ 44,435 | $ 16,880 | |
Key Metrics and Non-GAAP Financial Measures | |||||||
In addition to our results determined in accordance with US GAAP, we believe that certain non-GAAP financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin, are useful in evaluating our business. We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by total revenue. The following table presents a reconciliation of Adjusted EBITDA, a non-GAAP financial measure, to the most directly comparable financial measure prepared in accordance with US GAAP. | |||||||
Three months ended | Six months ended | ||||||
2022 | 2021 | 2022 | 2021 | ||||
Net profit (loss) | $ 4,300 | $ (1,659) | |||||
Net profit (loss) margin | 13 % | (7) % | (5) % | (9) % | |||
Depreciation and amortization | 926 | 149 | 1,599 | 331 | |||
Stock-based compensation | 4,138 | 1,440 | 5,730 | 1,720 | |||
Finance expense (income), net (a) | (13,306) | 1,602 | (15,617) | 3,171 | |||
Transaction related expenses (b) | 164 | — | 392 | — | |||
Acquisition related expenses (c) | 768 | — | 4,971 | — | |||
Other (d) | 1,518 | — | 1,610 | — | |||
Taxes on income | (168) | 346 | (205) | 525 | |||
Adjusted EBITDA | $ (1,660) | $ 1,878 | $ 2,152 | ||||
Adjusted EBITDA margin | (5) % | 8 % | (8) % | 5 % | |||
(a) | Finance expense (income), net consists primarily of remeasurement expense related to our foreign subsidiaries' monetary assets, liabilities and operating results, our interest expense and revaluation of our warrants. The unrealized gain from changes in the fair value of our warrants for the three months and six months period ended June 30, 2022 (unaudited) was |
(b) | Transaction related expenses consist of professional fees associated with the SPAC merger transaction and PIPE related SEC filings. |
(c) | Acquisition related expenses consists of professional fees associated with the acquisition of TVS. |
(d) | For the three months and six months ended June 30, 2022, "other" consists of exit costs for a former TVS employee, retention bonus expense for TVS employees and legal costs related to the Nielsen Claim. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/innovid-reports-second-quarter-2022-financial-results-301603162.html
SOURCE Innovid
FAQ
What were Innovid's revenue results for Q2 2022?
What is InnovidXP and how does it impact Innovid's growth?
What is the financial outlook for Innovid in Q3 2022?
How did CTV revenue perform in Q2 2022?
What is Innovid's adjusted EBITDA for Q2 2022?
